Company
Collegium Pharmaceutical, Inc.
Headquarters: Stoughton, MA, United States
Employees: 152
CEO: Mr. Joseph J. Ciaffoni
Market Cap
$975.5 Million
USD as of July 1, 2025
Collegium Pharmaceutical, Inc. Categories
United States Healthcare Drug Manufacturers—Specialty & GenericUnited States Healthcare United States Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $664.3 M |
| EBITDA | $340.4 M |
| Gross Profit TTM | $578.2 M |
| Profit Margin | 6.61% |
| Operating Margin | 13.71% |
| Quarterly Revenue Growth | 22.70% |
Stocks & Indices
Collegium Pharmaceutical, Inc. has the following listings and related stock indices.
Stock: NASDAQ: COLL wb_incandescent
Stock: FSX: 354 wb_incandescent